首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

2126330

分子感染疾病診斷市場：策略性洞察與預測（2026-2035）

Molecular Infectious Disease Diagnostics Market - Strategic Insights and Forecasts (2026-2035)

出版日期: 2026年08月03日 | 出版商:

Knowledge Sourcing Intelligence | 英文 171 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計分子感染疾病診斷市場規模將從 2026 年的 106 億美元成長到 2035 年的 221 億美元，複合年成長率為 8.5%。

分子感染疾病診斷市場正經歷一場重大變革，其驅動力在於快速、準確、全面的病原體檢測模式轉移。這一市場演變的特點是，人們日益認知到分子診斷對於確定合適的治療策略、合理使用抗生素以及進行公共衛生監測至關重要。聚合酵素鏈鎖反應(PCR) 技術、等溫擴增、次世代定序和人工智慧 (AI) 的整合，使得更快、更靈敏、多參數的同步傳染病檢查成為可能。由於感染疾病通常表現出重疊的症狀，醫療系統正將分子診斷置於優先地位，以實現病原體的快速識別、減少不必要的抗生素使用並改善患者預後。多參數症候群檢測組合的擴展，使得從單一檢體同時檢測多種病原體成為可能，從而改變了臨床檢查室的工作流程。公共衛生機構正在擴展其基因組監測基礎設施，推動了對能夠檢測新出現的病原體和監測抗生素抗藥性的高通量分子診斷平台的需求。透過對自動化「檢體到結果」系統、分散式分子檢測和整合數位診斷的大量投資，分子感染疾病診斷正在成為現代醫療保健服務和疫情應對的重要組成部分。

市場促進因素

感染疾病負擔日益加重是分子感染疾病診斷市場的主要驅動力。快速診斷直接影響治療決策，因為感染疾病往往在常規微生物學確診之前就已經進展。病原體鑑定延遲會導致經驗性治療延長和不必要的抗生素暴露增加，促使醫療機構擴大採用分子診斷。雖然傳統培養方法在臨床上仍然很重要，但其耗時過長限制了效用。診斷設備製造商正在擴展其快速PCR檢測板、自動化系統和抗藥性檢測產品，以支援抗生素使用方案，從而推動分子診斷應用的持續成長。多重綜合症檢測透過改變臨床檢查室的工作流程，進一步加速了市場成長。呼吸道感染、消化器官系統和血流感染疾病通常表現出重疊的臨床症狀，因此臨床檢查室需要能夠同時檢測多種病原體的技術。隨著檢查室努力提高效率並減少重複的單一標靶檢測，市場需求正轉向多重PCR檢測。擴大檢測範圍將提高檢體利用效率並縮短診斷流程。製造商正透過推出覆蓋範圍更廣、自動化程度更高、整合軟體更完善的症候群特異性檢測組合來應對挑戰。政府對疾病監測的投資正透過基礎建設支持市場擴張。全國性監測系統需要標準化的分子檢測，因為應對疫情越來越依賴快速識別病原體並闡明其基因組特徵。各國政府正根據從新冠肺炎疫情中汲取的經驗教訓，繼續投資分子檢查室基礎設施。公共衛生機構也需要可擴展的檢測能力，用於檢測流感、呼吸道融合細胞病毒、結核病、肝炎、抗生素抗藥性和新興感染疾病。診斷試劑製造商正持續開發能夠支援常規診斷和緊急應變的高通量分子診斷系統。自動化和數位化檢查室的整合正在提高檢測能力和工作流程效率。臨床檢查室面臨人手不足，而檢測數量卻持續成長。自動化分子診斷平台透過整合提取、擴增和檢測功能，簡化了檢測工作流程，從而減少了人工干預。因此，醫療保健系統正在投資於整合設備、數位連接和實驗室資訊系統，以處理整個「檢體到結果」的過程。

市場限制因素

自動化分子診斷平台需要大量的資金投入，這限制了其在預算有限的小規模醫院和檢查室中的應用。設備部署的高昂初始成本是資源匱乏環境下的一大障礙。法規核准流程和不斷變化的品質要求延長了新型分子傳染病檢查的商業化時間。嚴格的檢驗要求也延緩了創新技術的市場准入。雖然分子診斷可以識別病原體核酸，但通常需要進行補充微生物學檢測才能進行全面的抗生素敏感性評估，因此難以完全取代傳統的培養方法。整合工作流程的需求進一步增加了檢查室的複雜性。缺乏專業的實驗室技術人員和具備分子診斷專業知識的人員阻礙了先進平台的有效利用，限制了擴充性。

市場定義和範圍
感染疾病診斷產業概覽
分子感染疾病診斷的發展
主要市場趨勢
市場規模表現分析
市場預測
感染疾病負擔和未滿足的診斷需求
疾病盛行率和確診患者人數分析
測試數量分析
診斷流程與病人歷程分析
分子診斷在醫療機構的應用現狀

第4章市場動態

市場促進因素
市場限制因素
市場機遇
市場挑戰

第5章行業情勢

產業價值鏈分析
定價分析
還款狀態

第6章：創新趨勢

新型分子診斷技術
產品創新的整體概況
臨床試驗分析
診斷流程分析
技術藍圖
將人工智慧應用於分子診斷
數位健康與實驗室資訊學的整合

第7章監理情勢

法律規範
核准流程
合規要求

第8章：全球分子感染疾病診斷市場：展望分析

分析：按技術平台
分析：按測試類型
分析：依病原體類型
分析：依樣本類型
分析：透過臨床應用
分析：透過測試環境

第9章全球分子感染疾病診斷市場：細分市場分析

透過技術
- 聚合酵素鏈鎖反應（PCR）
  - 常規PCR
  - 即時PCR（qPCR）
  - 數位PCR（dPCR）
- 恒溫核酸增幅技術
- 次世代定序（NGS）
- DNA微陣列
- 其他分子技術
按測試類型
- 檢查室分子診斷
- 即時分子診斷
依產品
- 裝置
- 試劑和耗材
- 軟體和服務
疾病適應症
- 呼吸道感染疾病
- 性行為感染感染（STI）
- 醫療相關感染疾病（HAI）
- 胃腸道感染疾病
- 肝炎
- 其他感染疾病
依樣本類型
- 血
- 呼吸道檢體（痰液和拭子）
- 尿
- 航班
- 6. 唾液
- 其他檢體類型
最終用戶
- 醫院
- 臨床實驗室
- 學術研究機構
- 其他最終用戶

第10章全球分子感染疾病診斷市場：區域分析

北美洲
歐洲
亞太地區
南美洲
中東和非洲

第11章全球分子感染疾病診斷市場：國別分析

美國
加拿大
德國
英國
法國
義大利
西班牙
荷蘭
日本
中國
印度
韓國
澳洲
巴西
墨西哥
沙烏地阿拉伯
南非

第12章競爭格局

市佔率分析
策略趨勢
併購、合作與聯盟
新產品發布

第13章：公司簡介

F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Danaher Corporation
bioMerieux SA
Hologic, Inc.
QIAGEN NV
Thermo Fisher Scientific Inc.
Becton, Dickinson and Company（BD）
Siemens AG
Bio-Rad Laboratories, Inc.

第14章全球分子感染疾病診斷市場：商業預測分析

第15章投資與資金籌措分析

創業投資趨勢
政府資金
研發投資

第16章：未來展望

主要成長機遇
未來產業趨勢

簡介目錄

Product Code: KSI-009043

The Molecular Infectious Disease Diagnostics Market is expected to grow at a CAGR of 8.5% from a market value of USD 10.6 billion in 2026 to USD 22.1 billion in 2035.

The molecular infectious disease diagnostics market is undergoing significant transformation driven by the paradigm shift toward rapid, accurate, and comprehensive pathogen detection. The market's evolution is characterized by the growing recognition that molecular confirmation is essential for timely therapeutic decision-making, antimicrobial stewardship, and public health surveillance. The convergence of polymerase chain reaction technologies, isothermal amplification, next-generation sequencing, and artificial intelligence is enabling faster, more sensitive, and increasingly multiplexed infectious disease testing. Healthcare systems are prioritizing molecular diagnostics because infectious diseases frequently present with overlapping symptoms, and rapid pathogen identification reduces unnecessary antimicrobial exposure and improves patient outcomes. The expansion of multiplex syndromic testing panels is transforming clinical laboratory workflows by enabling simultaneous detection of numerous pathogens from a single specimen. Public health agencies are expanding genomic surveillance infrastructure, increasing demand for high-throughput molecular platforms capable of detecting emerging pathogens and monitoring antimicrobial resistance. The market is witnessing significant investment in automated sample-to-answer systems, decentralized molecular testing, and integrated digital diagnostics, positioning molecular infectious disease diagnostics as a critical component of modern healthcare delivery and pandemic preparedness.

Market Drivers

The increasing burden of infectious diseases represents the primary driver for the molecular infectious disease diagnostics market. Rapid diagnosis directly influences treatment decisions because infectious diseases frequently progress before conventional microbiological confirmation becomes available. Healthcare providers are increasingly adopting molecular diagnostics as delayed pathogen identification prolongs empirical therapy and increases unnecessary antimicrobial exposure. Traditional culture methods remain clinically important, yet longer turnaround times limit their usefulness during acute disease management. Diagnostic manufacturers are expanding rapid PCR panels, automated systems, and resistance detection assays that support antimicrobial stewardship programs, resulting in sustained growth in molecular diagnostic utilization. Multiplex syndromic testing is further accelerating market growth by transforming clinical laboratory workflows. Clinical laboratories require technologies capable of simultaneously detecting numerous pathogens because respiratory, gastrointestinal, and bloodstream infections often present with overlapping clinical manifestations. Demand is shifting toward multiplex PCR assays as laboratories attempt to improve efficiency while reducing repetitive single-target testing. Larger diagnostic menus also reduce specimen utilization and shorten diagnostic pathways. Manufacturers are responding by introducing broader syndromic panels with improved automation and integrated software. Government investment in disease surveillance is supporting market expansion through infrastructure development. National surveillance systems require standardized molecular testing because outbreak response increasingly depends on rapid pathogen identification and genomic characterization. Governments are continuing to invest in molecular laboratory infrastructure following lessons learned during the COVID-19 pandemic. Public health agencies also require scalable testing capacity for influenza, respiratory syncytial virus, tuberculosis, hepatitis, antimicrobial resistance, and emerging infectious diseases. Diagnostic manufacturers continue developing high-throughput molecular systems capable of supporting both routine diagnostics and emergency response. Automation and digital laboratory integration are improving testing capacity and workflow efficiency. Clinical laboratories face workforce shortages while diagnostic volumes continue increasing. Automated molecular platforms reduce manual intervention because integrated extraction, amplification, and detection simplify laboratory workflows. Healthcare systems are consequently investing in sample-to-answer instruments, digital connectivity, and laboratory information system integration.

Market Restraints

High capital investment requirements for automated molecular diagnostic platforms limit adoption among smaller hospitals and laboratories with constrained budgets. The substantial upfront costs for instrumentation create barriers for resource-constrained settings. Regulatory approval processes and evolving quality requirements increase commercialization timelines for novel molecular infectious disease assays. The rigorous validation requirements delay market entry for innovative technologies. Molecular diagnostics identify pathogen nucleic acids but often require complementary microbiological testing for comprehensive antimicrobial susceptibility assessment, limiting complete replacement of conventional culture methods. The need for integrated workflows creates additional complexity for laboratories. Shortages of specialized laboratory professionals and molecular diagnostics expertise constrain efficient utilization of advanced platforms, limiting scalability in many healthcare settings.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of multiplex molecular diagnostics and integrated testing workflows. PCR remains the dominant molecular technology because of its established analytical performance and extensive regulatory acceptance. Clinical laboratories are expanding PCR utilization beyond single-pathogen detection toward multiplex respiratory, gastrointestinal, bloodstream, and sexually transmitted infection panels that improve diagnostic efficiency. Real-time PCR (qPCR) provides quantitative detection for viral load monitoring and disease management. Digital PCR offers ultra-sensitive detection for low-abundance targets and rare mutation identification. Isothermal amplification technologies are gaining adoption for point-of-care and decentralized testing due to simplified instrumentation requirements. NGS is expanding for comprehensive pathogen surveillance, outbreak investigation, and antimicrobial resistance monitoring. The segment analysis reveals that reagents and consumables constitute the recurring revenue foundation because every molecular assay requires standardized extraction kits, amplification reagents, primers, probes, enzymes, quality controls, and disposable cartridges. Testing volumes are continuing to increase as hospitals expand syndromic testing and national surveillance programs strengthen molecular screening capacity. Respiratory infections represent the most established application segment because influenza, RSV, SARS-CoV-2, and numerous bacterial pathogens require rapid differentiation despite similar clinical presentation. Seasonal outbreaks are increasing laboratory testing demand while hospitals attempt to optimize patient isolation and antimicrobial utilization. Sexually transmitted infections, healthcare-associated infections, gastrointestinal infections, and hepatitis represent significant growth segments. Hospitals and clinical laboratories represent key end-user segments, with academic and research institutes playing a crucial role in assay development and validation. Point-of-care molecular diagnostics are expanding across decentralized healthcare settings. The integration of AI is becoming increasingly important because molecular diagnostic platforms generate complex data requiring efficient interpretation. AI is supporting result interpretation, quality control, and laboratory workflow optimization.

Competitive and Strategic Outlook

The competitive landscape features established molecular diagnostics and life science companies alongside specialized infectious disease and point-of-care providers. F. Hoffmann-La Roche is strategically distinguished by its comprehensive cobas molecular diagnostics ecosystem, integrating high-throughput PCR platforms with a broad infectious disease assay portfolio for centralized laboratories, continuing to expand automation, digital laboratory integration, and syndromic testing capabilities. Abbott differentiates itself through its diversified molecular diagnostics portfolio, combining centralized laboratory systems with rapid molecular testing platforms, continuing to expand infectious disease assay offerings while strengthening decentralized testing capabilities. Danaher leverages its operating companies, particularly Cepheid and Beckman Coulter, to provide integrated molecular diagnostics across centralized and near-patient settings, focusing on rapid PCR technologies, workflow automation, and continuous assay expansion. bioMerieux specializes in clinical microbiology and molecular infectious disease diagnostics, combining syndromic PCR testing with antimicrobial stewardship solutions, focusing on improving laboratory efficiency and accelerating pathogen identification for critical care settings. Hologic is recognized for its Panther molecular diagnostics platform, supporting high-throughput, fully automated infectious disease testing, continuing to expand its assay menu, particularly for sexually transmitted infections and respiratory diseases. QIAGEN differentiates itself through integrated sample preparation technologies and the QIAstat-Dx multiplex syndromic testing platform. Thermo Fisher Scientific offers a broad portfolio of molecular diagnostic instruments, PCR reagents, and genomic analysis solutions. BD combines molecular diagnostics with microbiology and specimen management solutions. Companies are pursuing product portfolio expansion through innovation in multiplex syndromic panels, rapid point-of-care molecular tests, antimicrobial resistance detection, and AI-enabled interpretation software. Strategic collaborations between diagnostic manufacturers, healthcare providers, and public health agencies are increasing, driven by the need for surveillance and outbreak preparedness. Recent key developments include Bruker launching MyGenius PRO, a fully automated PCR-based molecular diagnostics system delivering up to 144 results in 8 hours. Co-Diagnostics and its Saudi Arabia joint venture unveiled an automated manufacturing line for molecular diagnostic test kits. bioMerieux launched VetFire for equine veterinarians. Synthego announced its entry into the molecular biology and clinical diagnostic reagents market. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing Asia Pacific and emerging markets where healthcare infrastructure is expanding.

Short Conclusion

The molecular infectious disease diagnostics market is positioned for sustained growth driven by the convergence of infectious disease burden, multiplex testing adoption, government surveillance investment, and laboratory automation. The transition from single-pathogen testing toward comprehensive syndromic and multiplex diagnostic platforms represents a fundamental shift in infectious disease management. While challenges related to high capital costs, regulatory complexity, and workforce shortages persist, strategic investments in technology, automation, and partnerships are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with molecular infectious disease diagnostics evolving into a critical component of modern healthcare delivery, supporting rapid pathogen identification, antimicrobial stewardship, outbreak preparedness, and genomic surveillance across global healthcare systems.

Key Benefits of this Report

Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
Competitive positioning, strategies, and market share evaluation, and trade analysis
Revenue growth and forecast assessment across segments and regions
Company profiling including strategies, products, financials, and key developments

1. Executive Summary

1.1 Market Snapshot
1.2 Key Findings
1.3 Analyst Insights
1.4 Strategic Recommendations

2. Research Methodology

2.1 Research Design
2.2 Data Collection Methodology
2.3 Market Size Estimation
2.4 Forecasting Model
2.5 Assumptions & Limitations

3. Global Molecular Infectious Disease Diagnostics Market Overview, Size & Forecast

3.1 Market Definition & Scope
3.2 Infectious Disease Diagnostics Industry Overview
3.3 Evolution of Molecular Infectious Disease Diagnostics
3.4 Key Market Trends
3.5 Historical Market Size Analysis (2021-2025)
3.6 Market Forecast (2026-2035)
3.7 Infectious Disease Burden and Unmet Diagnostic Needs
3.8 Disease Prevalence and Diagnosed Patient Population Analysis
3.9 Testing Volume Analysis
3.10 Diagnostic Workflow and Patient Journey Analysis
3.11 Molecular Diagnostics Adoption Across Healthcare Settings

4. Market Dynamics

4.1 Market Drivers
4.2 Market Restraints
4.3 Market Opportunities
4.4 Market Challenges

5. Industry Landscape

5.1 Industry Value Chain Analysis
5.2 Pricing Analysis
5.3 Reimbursement Landscape

6. Innovation Landscape

6.1 Emerging Molecular Diagnostic Technologies
6.2 Product Innovation Landscape
6.3 Clinical Trial Analysis
6.4 Diagnostic Pipeline Analysis
6.5 Technology Roadmap
6.6 Artificial Intelligence Integration in Molecular Diagnostics
6.7 Digital Health and Laboratory Informatics Integration

7. Regulatory Landscape

7.1 Regulatory Framework
7.2 Approval Pathways
7.3 Compliance Requirements

8. Global Molecular Infectious Disease Diagnostics Market Landscape Analysis

8.1 Analysis by Technology Platform
8.2 Analysis by Test Type
8.3 Analysis by Pathogen Type
8.4 Analysis by Sample Type
8.5 Analysis by Clinical Application
8.6 Analysis by Testing Setting

9. Global Molecular Infectious Disease Diagnostics Market Segment Analysis (2021-2035)

9.1 By Technology
- 9.1.1 Polymerase Chain Reaction (PCR)
  - 9.1.1.1 Conventional PCR
  - 9.1.1.2 Real-Time PCR (qPCR)
  - 9.1.1.3 Digital PCR (dPCR)
- 9.1.2 Isothermal Nucleic Acid Amplification Technologies
- 9.1.3 Next-Generation Sequencing (NGS)
- 9.1.4 DNA Microarrays
- 9.1.5 Other Molecular Technologies
9.2 By Test Type
- 9.2.1 Laboratory-Based Molecular Diagnostics
- 9.2.2 Point-of-Care Molecular Diagnostics
9.3 By Product
- 9.3.1 Instruments
- 9.3.2 Reagents & Consumables
- 9.3.3 Software & Services
9.4 By Disease Indication
- 9.4.1 Respiratory Infections
- 9.4.2 Sexually Transmitted Infections (STIs)
- 9.4.3 Healthcare-Associated Infections (HAIs)
- 9.4.4 Gastrointestinal Infections
- 9.4.5 Hepatitis
- 9.4.6 Other Infectious Diseases
9.6 By Sample Type
- 9.6.1 Blood
- 9.6.2 Respiratory specimens (Sputum & Swabs)
- 9.6.3 Urine
- 9.6.4 Stool
- 9.6.5 6 Saliva
- 9.6.6 Other Sample Types
9.7 By End User
- 9.7.1 Hospitals
- 9.7.2 Clinical Laboratories
- 9.7.3 Academic & Research Institutes
- 9.7.4 Other End Users

10. Global Molecular Infectious Disease Diagnostics Market Geographical Analysis (2021-2035)

10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 South America
10.5 Middle East & Africa

11. Global Molecular Infectious Disease Diagnostics Market Country Analysis (2021-2035)

11.1 United States
11.2 Canada
11.3 Germany
11.4 United Kingdom
11.5 France
11.6 Italy
11.7 Spain
11.8 Netherlands
11.9 Japan
11.10 China
11.11 India
11.12 South Korea
11.13 Australia
11.14 Brazil
11.15 Mexico
11.16 Saudi Arabia
11.17 South Africa

12. Competitive Landscape

12.1 Market Share Analysis
12.2 Strategic Developments
12.3 Mergers & Acquisitions, Partnerships & Collaborations
12.4 Product Launches

13. Company Profiles

13.1 F. Hoffmann-La Roche Ltd.
- 13.1.1 Company Overview
- 13.1.2 Financials
- 13.1.3 Product Portfolio
- 13.1.4 Recent Developments
13.2 Abbott Laboratories
13.3 Danaher Corporation
13.4 bioMerieux SA
13.5 Hologic, Inc.
13.6 QIAGEN N.V.
13.7 Thermo Fisher Scientific Inc.
13.8 Becton, Dickinson and Company (BD)
13.9 Siemens AG
13.10 Bio-Rad Laboratories, Inc.